arexvy rsv vaccine news

GSK, RSV and Shingles

GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines

GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults (aged 50 years and older).

MarketWatch · 3d

GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine

GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.

Business Insider · 2d

GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines

GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the

Reuters on MSN · 2d

GSK's RSV, Shingles vaccines show on-par immune response in joint trial

(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.

Seeking Alpha on MSN · 2d

GSK posts late-stage trial win for co-administered RSV and shingles vaccines

GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older.

The American Journal of Managed Care3d

New RSV Vaccine Is Likely Cost-Effective for Older Adults, Study Finds

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

EurekAlert!15d

New RSV vaccine for older adults can result in individual and societal cost savings, benefits

evaluated newly approved RSV vaccines: Arexvy, manufactured by GSK, and Abrysvo, manufactured by Pfizer. The study did not include a third approved vaccine, Moderna's mRESVIA. The vaccines are ...

PMLiVE22d

GSK’s RSV vaccine Arexvy approved by EC for use in adults aged 50 to 59 years

GSK’s Arexvy has become the first respiratory syncytial virus (RSV) vaccine to be approved by the European Commission (EC) for use in adults aged 50 to 59 years who are at an increased risk of ...

Saugeen Times3d

Ask the Pharmacist – RSV vaccine

RSV is a common virus that affects the respiratory system primarily amongst infants, young children and older adults. Though ...

Yahoo Finance22d

GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years

GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 50-59 years. The vaccine ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results